Net Income

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

A new Regina clinic uses high-tech chairs to fight a silent health epidemic, blending innovation with a mission to break the billion-dollar taboo of incontinence.

China Automotive Systems' new high-torque motor isn't just a component; it's a strategic play for the future of autonomous trucking and a challenge to incumbents.

Beyond straight teeth, a new aligner offers non-surgical jaw correction for adults, shaking up a multi-billion dollar market. Is this the future?

Getlink's latest figures show a slowdown in cross-Channel traffic, revealing deep strains in the automotive sector and growing consumer caution.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

As Airbus doubles down in China, the partnership between Paris and Beijing reveals a pragmatic model balancing deep economic ties with a bold geopolitical vision.

The landmark partnership validates China's biotech prowess and injects Takeda's pipeline with next-gen cancer therapies, signaling a major industry shift.

With a high-grade Alaskan asset secured and a $44M war chest, Vizsla Copper is making a bold move in the race for North American resource security.

With new funding, Japan's Helical Fusion is racing to build a fusion plant by the 2030s. Can its unique stellarator technology win the clean energy race?

SoFi's surprise $1.5 billion stock sale sends shares tumbling. Is this a bold play for market dominance or a sign of fintech's increasing capital hunger?

For the seventh year, Aptar is named a top responsible company. Beyond the award, this is a look at how sustained ESG strategy creates a powerful competitive advantage.

With a clear FDA path for its breakthrough drug, Praxis is set to disrupt the stagnant, multi-billion-dollar essential tremor market.

A Nasdaq firm is using AI real estate software profits to build a massive Solana treasury. Capital Currents unpacks DFDV's radical dual-pronged strategy.

Baxter is buying back billions in debt, a strategic move to clean its balance sheet. But with operational issues mounting, is it enough to win back investors?

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

Immunome is using strategic stock grants to lure top talent. We analyze why this move is critical for its pipeline and what it means for investors.

With its CFO departing after a major strategic pivot, AAR CORP. names a 13-year insider as his interim replacement. What does this signal for investors?

With $15M in new funding and seasoned mining execs on board, Getty Copper is now debt-free and poised to unlock the potential of its vast copper assets.